<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01445171</url>
  </required_header>
  <id_info>
    <org_study_id>2009-01</org_study_id>
    <nct_id>NCT01445171</nct_id>
  </id_info>
  <brief_title>Surgical Treatment of Aortic Stenosis With a Next Generation Surgical Aortic Valve</brief_title>
  <acronym>TRITON</acronym>
  <official_title>Surgical Treatment of Aortic Stenosis With a Next Generation Surgical Aortic Valve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical investigation is to confirm that the safety and performance of
      the EDWARDS INTUITY Valve System.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two-phase, non-randomized, prospective, single arm, multi-center clinical
      investigation. Each subject in Phase 1 and Phase 2 is consented for a period of 5 years. All
      subjects will be assessed for clinical follow-up at the following intervals: Discharge, 1
      month, 3 months, 1 year and annually thereafter until 5 years of follow-up is achieved per
      subject.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Early Adverse Events</measure>
    <time_frame>Events occuring within 30 days of procedure</time_frame>
    <description>Number of early adverse events occurring within 30 days of procedure divided by the total number of enrolled subjects times 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Late Adverse Events</measure>
    <time_frame>Events occurring &gt;= 31 days and up through 5 years post-implant</time_frame>
    <description>Number of late adverse events divided by the total number of late patient years times 100. Late patient years are calculated from 31 days post-implant to the date of the last contact (follow up or adverse event).</description>
  </primary_outcome>
  <other_outcome>
    <measure>Number of Subject's With Device Technical Success</measure>
    <time_frame>At time of surgery, an average of 3 hours</time_frame>
    <description>Device technical success is defined as the successful delivery and deployment of one bioprosthesis with one delivery system with a maximum of two attempts.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Subject's With Procedural Success</measure>
    <time_frame>Discharge(an average of 13 days) or 10 days post-implant, whichever comes first</time_frame>
    <description>Procedure success is defined as device technical success followed by the absence of adverse events requiring device reoperation, requiring implantation of permanent pacemaker, or subject death.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's New York Heart Association (NYHA) Functional Class Compared to Baseline</measure>
    <time_frame>1 Month, 3 Months, 1 Year, 2 Years, 3 Years, 4 Years, and 5 Years post-implant</time_frame>
    <description>The New York Heart Association (NYHA) functional classification system relates symptoms to everyday activities and the patient's quality of life.
Class I. No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath).
Class II. Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath).
Class III. Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea.
Class IV. Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Score on the EQ-5D- Quality of Life Questionnaire Over Time</measure>
    <time_frame>Baseline, 3 Months, and 1 Year post-implant</time_frame>
    <description>The EQ-5D is a standardized questionnaire that asks subjects to rate themselves (no problems, some problems, extreme problems) on mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The scale is indexed and ranges from a minimum of 0.275 and a maximum of 1.000. A lower number indicates the participants experiences more problems and a higher number indicates the participants experiences fewer problems.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Mean Systolic Gradient Measurements Over Time.</measure>
    <time_frame>Discharge (an average of 13 days), 1 Month, 3 Months, 1 Year, 2 Years, 3 Years, 4 Years, and 5 Years post-implant</time_frame>
    <description>Mean gradient is the average flow of blood through the aortic valve measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. Mean gradient values depend on the size and type of valve.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Effective Orifice Area Measurements Over Time.</measure>
    <time_frame>Discharge (an average of 13 days), 1 Month, 3 Months, 1 Year, 2 Years, 3 Years, 4 Years, and 5 Years post-implant</time_frame>
    <description>Effective orifice area represents the cross-sectional area of the blood flow downstream of the aortic valve. Effective orifice area is evaluated by echocardiography over time.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Amount of Aortic Valvular Regurgitation Over Time</measure>
    <time_frame>Discharge (an average of 13 days), 1 Month, 3 Months, 1 Year, 2 Years, 3 Years, 4 Years, and 5 Years post-implant</time_frame>
    <description>Aortic valvular regurgitation occurs when the aortic valve in the heart does not close tightly allowing some of the blood that was pumped out of the heart to leak back into it. Aortic valvular regurgitation is evaluated by echocardiography over time. It is assessed on a scale from 0 to 4, where 0 represents no regurgitation and 4 represents severe regurgitation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average White Blood Cell Count Measurement Over Time.</measure>
    <time_frame>Baseline, 3 Months, 1 Year, and 5 Years post-implant</time_frame>
    <description>Laboratory analysis of White Blood Cell Count on blood drawn from subject; WBC fight infection.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Red Blood Cells Count Over Time.</measure>
    <time_frame>Baseline, 3 Months, 1 Year, and 5 Years post-implant</time_frame>
    <description>Laboratory Analysis of Red Blood Cell Count on blood drawn from subjects; RBC carry oxygen.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Hemoglobin Count Over Time.</measure>
    <time_frame>Baseline, 3 Months, 1 Year, and 5 Years post-implant</time_frame>
    <description>Laboratory Analysis of Hemoglobin Count on blood drawn from subjects. Hemoglobin is an oxygen-carrying protein in red blood cells.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Hematocrit Percentage Over Time.</measure>
    <time_frame>Baseline, 3 Months, 1 Year, and 5 Years post-implant</time_frame>
    <description>Laboratory Analysis of Hematocrit Percentage on blood drawn from subjects. Hematocrit is the proportion of red blood cells to the fluid component (plasma) in the blood.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Platelet Count Over Time.</measure>
    <time_frame>Baseline, 3 Months, 1 Year, and 5 Years post-implant</time_frame>
    <description>Laboratory Analysis of Platelet Count on blood drawn from subjects; platelets help with blood clotting.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Reticulocytes Percentage Over Time.</measure>
    <time_frame>Baseline, 3 Months, 1 Year, and 5 Years post-implant</time_frame>
    <description>Reticulocytes are immature red blood cells; a reticulocyte blood test measures the amount of these cells in the blood.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Haptoglobin Measurement Over Time.</measure>
    <time_frame>Baseline, 3 Months, 1 Year, and 5 Years post-implant</time_frame>
    <description>Laboratory Analysis of Haptoglobin on blood drawn from subjects; Haptoglobin is a protein produced by the liver.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject's Average Serum LDH Measurement Over Time.</measure>
    <time_frame>Baseline, 3 Months, 1 Year, and 5 Years post-implant</time_frame>
    <description>The lactate dehydrogenase (LDH) test looks for signs of damage to the body's tissues.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">295</enrollment>
  <condition>Aortic Valve Stenosis With Insufficiency</condition>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Study Valve</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects act as own control</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aortic Valve Replacement with EDWARDS INTUITY Valve System</intervention_name>
    <description>Aortic Valve bioprosthesis</description>
    <arm_group_label>Study Valve</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria:

        Inclusion Criteria:

          -  18 years or older

          -  Aortic stenosis or stenosis-insufficiency of aortic valve requiring a planned
             replacement as indicated in the preoperative evaluation;

          -  Scheduled to undergo planned aortic valve replacement with or without concomitant
             coronary bypass surgery, MAZE procedure, septal myectomy, pacemaker/ICD implant and or
             atrial appendage occlusion/removal.

          -  Signed and dated the informed consent form prior to investigation procedures;

          -  Geographically stable and agrees to attend Follow up assessments at the hospital of
             surgical services for a maximum of 5 years.

        Exclusion Criteria:

          -  Pure aortic insufficiency

          -  Requires emergency surgery

          -  Aneurysm of the aortic root and/or ascending aorta requiring surgical intervention

          -  Left ventricular ejection fraction of ≤ 25%

          -  Active endocarditis within 3 months prior to the scheduled aortic valve replacement
             surgery

          -  Concomitant valve (mitral, tricuspid, or pulmonic) disease requiring repair with an
             annuloplasty ring or replacement with prosthesis

          -  Prior mitral, tricuspid or pulmonic valve surgery, which included implantation of a
             bioprosthetic valve, mechanical valve, or annuloplasty ring.

          -  Myocardial infarction (MI) within 1 month prior to the scheduled aortic valve
             replacement surgery

          -  Previously implanted with EDWARDS INTUITY Aortic valve; alcohol or drug abuser

          -  Disease limiting life expectancy to less than 12 months

          -  Pregnant or lactating

          -  Currently participating in another drug or device clinical investigation;

          -  Documented blood diatheses

          -  Requires non-cardiac procedures such as carotid procedures or mediastinal tumor
             removal

          -  Had a stroke or transient ischemic attack (TIA) within 6-months prior to scheduled
             aortic valve replacement surgery

          -  Study site pre-operative echocardiographic assessment shows evidence of an
             intracardiac mass, thrombus, or vegetation

          -  Hemodynamic or respiratory instability requiring inotropic support, mechanical
             circulatory support, or mechanical ventilation within 30 days of procedure

          -  Documented renal insufficiency as determined by Serum creatinine ≥ 200 µmol/L (2.27
             mg/dL) at screening or end-stage renal disease requiring chronic dialysis

          -  Documented hyperparathyroidism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof Axel Haverich</last_name>
    <role>Study Director</role>
    <affiliation>MHH Hannover</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AKH Vienna-Allgemeines Krankenhaus der Stadt Wien; University Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerchoff Klinik-Bad Nauheim</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHH-Medizinische Hoschschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Uniklink Koln-Klinik und Poliklinik fur Herz und Thoraxzchirurgie</name>
      <address>
        <city>Koeln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Leipzig: Herzzentrum Leipzig Gmbh</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitat Muchen-Grosshadern; Clinic at the University of Munich</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>Switzerland</country>
  </removed_countries>
  <link>
    <url>https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure/classes-of-heart-failure</url>
    <description>New York Heart Association Classification</description>
  </link>
  <link>
    <url>https://euroqol.org/eq-5d-instruments/</url>
    <description>Measure of Health Status Survey (EQ-5D)</description>
  </link>
  <results_reference>
    <citation>Laufer G, Haverich A, Andreas M, Mohr FW, Walther T, Shrestha M, Rahmanian P, Holzhey D, Roth M, Schmitz C, Schramm R, Giot C, Wahlers TCW. Long-term outcomes of a rapid deployment aortic valve: data up to 5 years. Eur J Cardiothorac Surg. 2017 Aug 1;52(2):281-287. doi: 10.1093/ejcts/ezx103.</citation>
    <PMID>28453629</PMID>
  </results_reference>
  <results_reference>
    <citation>Haverich A, Wahlers TC, Borger MA, Shrestha M, Kocher AA, Walther T, Roth M, Misfeld M, Mohr FW, Kempfert J, Dohmen PM, Schmitz C, Rahmanian P, Wiedemann D, Duhay FG, Laufer G. Three-year hemodynamic performance, left ventricular mass regression, and prosthetic-patient mismatch after rapid deployment aortic valve replacement in 287 patients. J Thorac Cardiovasc Surg. 2014 Dec;148(6):2854-60. doi: 10.1016/j.jtcvs.2014.07.049. Epub 2014 Aug 1.</citation>
    <PMID>25218544</PMID>
  </results_reference>
  <results_reference>
    <citation>Kocher AA, Laufer G, Haverich A, Shrestha M, Walther T, Misfeld M, Kempfert J, Gillam L, Schmitz C, Wahlers TC, Wippermann J, Mohr FW, Roth M, Skwara A, Rahmanian P, Wiedemann D, Borger MA. One-year outcomes of the Surgical Treatment of Aortic Stenosis With a Next Generation Surgical Aortic Valve (TRITON) trial: a prospective multicenter study of rapid-deployment aortic valve replacement with the EDWARDS INTUITY Valve System. J Thorac Cardiovasc Surg. 2013 Jan;145(1):110-5; discussion 115-6. doi: 10.1016/j.jtcvs.2012.07.108. Epub 2012 Oct 8.</citation>
    <PMID>23058665</PMID>
  </results_reference>
  <results_reference>
    <citation>Wahlers TCW, Andreas M, Rahmanian P, Candolfi P, Zemanova B, Giot C, Ferrari E, Laufer G. Outcomes of a Rapid Deployment Aortic Valve Versus Its Conventional Counterpart: A Propensity-Matched Analysis. Innovations (Phila). 2018 May/Jun;13(3):177-183. doi: 10.1097/IMI.0000000000000509.</citation>
    <PMID>29912142</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 5, 2011</study_first_submitted>
  <study_first_submitted_qc>September 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2011</study_first_posted>
  <results_first_submitted>January 15, 2020</results_first_submitted>
  <results_first_submitted_qc>February 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 17, 2020</results_first_posted>
  <last_update_submitted>February 6, 2020</last_update_submitted>
  <last_update_submitted_qc>February 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic Valve Replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 15, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT01445171/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>INTUITY Aortic Valve and INTUITY Delivery System</title>
          <description>The EDWARDS INTUITY Aortic Valve models 8300ACA and 8300ACB, and the EDWARDS INTUITY Delivery System models 8300DCA and 8300DCB are intended for use in subjects with aortic stenosis or stenosis-insufficiency requiring primary replacement of the native aortic valve.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="295"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Implanted With Study Device</title>
              <participants_list>
                <participants group_id="P1" count="287"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subjects declined to return for followup</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consented but did not receive device</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The outcome is reported for subjects who received the Magna Mitral, Model 7000TFX device where data is available.</population>
      <group_list>
        <group group_id="B1">
          <title>INTUITY Aortic Valve and INTUITY Delivery System</title>
          <description>The EDWARDS INTUITY Aortic Valve models 8300ACA and 8300ACB, and the EDWARDS INTUITY Delivery System models 8300DCA and 8300DCB are intended for use in subjects with aortic stenosis or stenosis-insufficiency requiring primary replacement of the native aortic valve.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="287"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="287"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.3" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="287"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Early Adverse Events</title>
        <description>Number of early adverse events occurring within 30 days of procedure divided by the total number of enrolled subjects times 100.</description>
        <time_frame>Events occuring within 30 days of procedure</time_frame>
        <population>The outcome is reported for subjects who received the Edwards Intuity model 8300ACA or 8300ACB device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>INTUITY Aortic Valve and INTUITY Delivery System</title>
            <description>The EDWARDS INTUITY Aortic Valve models 8300ACA and 8300ACB, and the EDWARDS INTUITY Delivery System models 8300DCA and 8300DCB are intended for use in subjects with aortic stenosis or stenosis-insufficiency requiring primary replacement of the native aortic valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Early Adverse Events</title>
          <description>Number of early adverse events occurring within 30 days of procedure divided by the total number of enrolled subjects times 100.</description>
          <population>The outcome is reported for subjects who received the Edwards Intuity model 8300ACA or 8300ACB device where data is available.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Cause Mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Valve Related Mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thromboembolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Valve Thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Paravalvular Leak (OPC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemolysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endocarditis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Structural Valve Deterioration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reoperation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Explant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Valve Related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Late Adverse Events</title>
        <description>Number of late adverse events divided by the total number of late patient years times 100. Late patient years are calculated from 31 days post-implant to the date of the last contact (follow up or adverse event).</description>
        <time_frame>Events occurring &gt;= 31 days and up through 5 years post-implant</time_frame>
        <population>The outcome is reported for subjects who received the Edwards Intuity model 8300ACA or 8300ACB device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>INTUITY Aortic Valve and INTUITY Delivery System</title>
            <description>The EDWARDS INTUITY Aortic Valve models 8300ACA and 8300ACB, and the EDWARDS INTUITY Delivery System models 8300DCA and 8300DCB are intended for use in subjects with aortic stenosis or stenosis-insufficiency requiring primary replacement of the native aortic valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Late Adverse Events</title>
          <description>Number of late adverse events divided by the total number of late patient years times 100. Late patient years are calculated from 31 days post-implant to the date of the last contact (follow up or adverse event).</description>
          <population>The outcome is reported for subjects who received the Edwards Intuity model 8300ACA or 8300ACB device where data is available.</population>
          <units>Percentage of late adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Cause Mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trial Valve Related Mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thromboembolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Valve Thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Paravalvular Leak (OPC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemolysis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endocarditis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Structural Valve Deterioration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reoperation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Explant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Valve Related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Subject's With Device Technical Success</title>
        <description>Device technical success is defined as the successful delivery and deployment of one bioprosthesis with one delivery system with a maximum of two attempts.</description>
        <time_frame>At time of surgery, an average of 3 hours</time_frame>
        <population>This outcome is reported for enrolled subjects where data is available. Subjects were considered enrolled after meeting all the enrollment criteria, signing the informed consent, and after the surgeon sized the aortic annulus, and determined that the bioprosthesis could be implanted.</population>
        <group_list>
          <group group_id="O1">
            <title>INTUITY Aortic Valve and INTUITY Delivery System</title>
            <description>The EDWARDS INTUITY Aortic Valve models 8300ACA and 8300ACB, and the EDWARDS INTUITY Delivery System models 8300DCA and 8300DCB are intended for use in subjects with aortic stenosis or stenosis-insufficiency requiring primary replacement of the native aortic valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subject's With Device Technical Success</title>
          <description>Device technical success is defined as the successful delivery and deployment of one bioprosthesis with one delivery system with a maximum of two attempts.</description>
          <population>This outcome is reported for enrolled subjects where data is available. Subjects were considered enrolled after meeting all the enrollment criteria, signing the informed consent, and after the surgeon sized the aortic annulus, and determined that the bioprosthesis could be implanted.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Subject's With Procedural Success</title>
        <description>Procedure success is defined as device technical success followed by the absence of adverse events requiring device reoperation, requiring implantation of permanent pacemaker, or subject death.</description>
        <time_frame>Discharge(an average of 13 days) or 10 days post-implant, whichever comes first</time_frame>
        <population>This outcome is reported for enrolled subjects where data is available. Subjects were considered enrolled after meeting all the enrollment criteria, signing the informed consent, and after the surgeon sized the aortic annulus, and determined that the bioprosthesis could be implanted.</population>
        <group_list>
          <group group_id="O1">
            <title>INTUITY Aortic Valve and INTUITY Delivery System</title>
            <description>The EDWARDS INTUITY Aortic Valve models 8300ACA and 8300ACB, and the EDWARDS INTUITY Delivery System models 8300DCA and 8300DCB are intended for use in subjects with aortic stenosis or stenosis-insufficiency requiring primary replacement of the native aortic valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subject's With Procedural Success</title>
          <description>Procedure success is defined as device technical success followed by the absence of adverse events requiring device reoperation, requiring implantation of permanent pacemaker, or subject death.</description>
          <population>This outcome is reported for enrolled subjects where data is available. Subjects were considered enrolled after meeting all the enrollment criteria, signing the informed consent, and after the surgeon sized the aortic annulus, and determined that the bioprosthesis could be implanted.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's New York Heart Association (NYHA) Functional Class Compared to Baseline</title>
        <description>The New York Heart Association (NYHA) functional classification system relates symptoms to everyday activities and the patient's quality of life.
Class I. No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath).
Class II. Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath).
Class III. Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea.
Class IV. Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.</description>
        <time_frame>1 Month, 3 Months, 1 Year, 2 Years, 3 Years, 4 Years, and 5 Years post-implant</time_frame>
        <population>The outcome is reported for subjects who received the Edwards Intuity model 8300ACA or 8300ACB device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>INTUITY Aortic Valve and INTUITY Delivery System</title>
            <description>The EDWARDS INTUITY Aortic Valve models 8300ACA and 8300ACB, and the EDWARDS INTUITY Delivery System models 8300DCA and 8300DCB are intended for use in subjects with aortic stenosis or stenosis-insufficiency requiring primary replacement of the native aortic valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's New York Heart Association (NYHA) Functional Class Compared to Baseline</title>
          <description>The New York Heart Association (NYHA) functional classification system relates symptoms to everyday activities and the patient's quality of life.
Class I. No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath).
Class II. Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath).
Class III. Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea.
Class IV. Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.</description>
          <population>The outcome is reported for subjects who received the Edwards Intuity model 8300ACA or 8300ACB device where data is available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 Month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="194"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Same</title>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="262"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="189"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Same</title>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="191"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Same</title>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="238"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="180"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Same</title>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="225"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Same</title>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="207"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Same</title>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Same</title>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average Score on the EQ-5D- Quality of Life Questionnaire Over Time</title>
        <description>The EQ-5D is a standardized questionnaire that asks subjects to rate themselves (no problems, some problems, extreme problems) on mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The scale is indexed and ranges from a minimum of 0.275 and a maximum of 1.000. A lower number indicates the participants experiences more problems and a higher number indicates the participants experiences fewer problems.</description>
        <time_frame>Baseline, 3 Months, and 1 Year post-implant</time_frame>
        <population>The outcome is reported for subjects who received the Edwards Intuity model 8300ACA or 8300ACB device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline and 3 Months Follow-Up</title>
            <description>The EDWARDS INTUITY Aortic Valve models 8300ACA and 8300ACB, and the EDWARDS INTUITY Delivery System models 8300DCA and 8300DCB are intended for use in subjects with aortic stenosis or stenosis-insufficiency requiring primary replacement of the native aortic valve.</description>
          </group>
          <group group_id="O2">
            <title>Baseline and 1 Year Follow-Up</title>
            <description>The EDWARDS INTUITY Aortic Valve models 8300ACA and 8300ACB, and the EDWARDS INTUITY Delivery System models 8300DCA and 8300DCB are intended for use in subjects with aortic stenosis or stenosis-insufficiency requiring primary replacement of the native aortic valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Score on the EQ-5D- Quality of Life Questionnaire Over Time</title>
          <description>The EQ-5D is a standardized questionnaire that asks subjects to rate themselves (no problems, some problems, extreme problems) on mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The scale is indexed and ranges from a minimum of 0.275 and a maximum of 1.000. A lower number indicates the participants experiences more problems and a higher number indicates the participants experiences fewer problems.</description>
          <population>The outcome is reported for subjects who received the Edwards Intuity model 8300ACA or 8300ACB device where data is available.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="0.20"/>
                    <measurement group_id="O2" value="0.79" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-Up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" spread="0.18"/>
                    <measurement group_id="O2" value="0.83" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average Mean Systolic Gradient Measurements Over Time.</title>
        <description>Mean gradient is the average flow of blood through the aortic valve measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. Mean gradient values depend on the size and type of valve.</description>
        <time_frame>Discharge (an average of 13 days), 1 Month, 3 Months, 1 Year, 2 Years, 3 Years, 4 Years, and 5 Years post-implant</time_frame>
        <population>The outcome is reported for subjects who received the Edwards Intuity model 8300ACA or 8300ACB device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>INTUITY Aortic Valve and INTUITY Delivery System</title>
            <description>The EDWARDS INTUITY Aortic Valve models 8300ACA and 8300ACB, and the EDWARDS INTUITY Delivery System models 8300DCA and 8300DCB are intended for use in subjects with aortic stenosis or stenosis-insufficiency requiring primary replacement of the native aortic valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Mean Systolic Gradient Measurements Over Time.</title>
          <description>Mean gradient is the average flow of blood through the aortic valve measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. Mean gradient values depend on the size and type of valve.</description>
          <population>The outcome is reported for subjects who received the Edwards Intuity model 8300ACA or 8300ACB device where data is available.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discharge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="226"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="224"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="230"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="186"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average Effective Orifice Area Measurements Over Time.</title>
        <description>Effective orifice area represents the cross-sectional area of the blood flow downstream of the aortic valve. Effective orifice area is evaluated by echocardiography over time.</description>
        <time_frame>Discharge (an average of 13 days), 1 Month, 3 Months, 1 Year, 2 Years, 3 Years, 4 Years, and 5 Years post-implant</time_frame>
        <population>The outcome is reported for subjects who received the Edwards Intuity model 8300ACA or 8300ACB device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>INTUITY Aortic Valve and INTUITY Delivery System</title>
            <description>The EDWARDS INTUITY Aortic Valve models 8300ACA and 8300ACB, and the EDWARDS INTUITY Delivery System models 8300DCA and 8300DCB are intended for use in subjects with aortic stenosis or stenosis-insufficiency requiring primary replacement of the native aortic valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Effective Orifice Area Measurements Over Time.</title>
          <description>Effective orifice area represents the cross-sectional area of the blood flow downstream of the aortic valve. Effective orifice area is evaluated by echocardiography over time.</description>
          <population>The outcome is reported for subjects who received the Edwards Intuity model 8300ACA or 8300ACB device where data is available.</population>
          <units>Centimeters Squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discharge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="178"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="211"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="178"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Amount of Aortic Valvular Regurgitation Over Time</title>
        <description>Aortic valvular regurgitation occurs when the aortic valve in the heart does not close tightly allowing some of the blood that was pumped out of the heart to leak back into it. Aortic valvular regurgitation is evaluated by echocardiography over time. It is assessed on a scale from 0 to 4, where 0 represents no regurgitation and 4 represents severe regurgitation.</description>
        <time_frame>Discharge (an average of 13 days), 1 Month, 3 Months, 1 Year, 2 Years, 3 Years, 4 Years, and 5 Years post-implant</time_frame>
        <population>The outcome is reported for subjects who received the Edwards Intuity model 8300ACA or 8300ACB device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>INTUITY Aortic Valve and INTUITY Delivery System</title>
            <description>The EDWARDS INTUITY Aortic Valve models 8300ACA and 8300ACB, and the EDWARDS INTUITY Delivery System models 8300DCA and 8300DCB are intended for use in subjects with aortic stenosis or stenosis-insufficiency requiring primary replacement of the native aortic valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Amount of Aortic Valvular Regurgitation Over Time</title>
          <description>Aortic valvular regurgitation occurs when the aortic valve in the heart does not close tightly allowing some of the blood that was pumped out of the heart to leak back into it. Aortic valvular regurgitation is evaluated by echocardiography over time. It is assessed on a scale from 0 to 4, where 0 represents no regurgitation and 4 represents severe regurgitation.</description>
          <population>The outcome is reported for subjects who received the Edwards Intuity model 8300ACA or 8300ACB device where data is available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discharge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="257"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 None/+1 Trivial</title>
                  <measurement_list>
                    <measurement group_id="O1" value="244"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+2 Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+3 Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+4 Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 None/+1 Trivial</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+2 Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+3 Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+4 Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 None/+1 Trivial</title>
                  <measurement_list>
                    <measurement group_id="O1" value="235"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+2 Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+3 Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+4 Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="248"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 None/+1 Trivial</title>
                  <measurement_list>
                    <measurement group_id="O1" value="231"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+2 Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+3 Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+4 Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 None/+1 Trivial</title>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+2 Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+3 Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+4 Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 None/+1 Trivial</title>
                  <measurement_list>
                    <measurement group_id="O1" value="177"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+2 Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+3 Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+4 Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="140"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 None/+1 Trivial</title>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+2 Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+3 Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+4 Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0 None/+1 Trivial</title>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+2 Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+3 Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>+4 Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average White Blood Cell Count Measurement Over Time.</title>
        <description>Laboratory analysis of White Blood Cell Count on blood drawn from subject; WBC fight infection.</description>
        <time_frame>Baseline, 3 Months, 1 Year, and 5 Years post-implant</time_frame>
        <population>The outcome is reported for subjects who received the Edwards Intuity model 8300ACA or 8300ACB device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>INTUITY Aortic Valve and INTUITY Delivery System</title>
            <description>The EDWARDS INTUITY Aortic Valve models 8300ACA and 8300ACB, and the EDWARDS INTUITY Delivery System models 8300DCA and 8300DCB are intended for use in subjects with aortic stenosis or stenosis-insufficiency requiring primary replacement of the native aortic valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average White Blood Cell Count Measurement Over Time.</title>
          <description>Laboratory analysis of White Blood Cell Count on blood drawn from subject; WBC fight infection.</description>
          <population>The outcome is reported for subjects who received the Edwards Intuity model 8300ACA or 8300ACB device where data is available.</population>
          <units>10^3 cells/microliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.80" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="257"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.97" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.10" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.31" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average Red Blood Cells Count Over Time.</title>
        <description>Laboratory Analysis of Red Blood Cell Count on blood drawn from subjects; RBC carry oxygen.</description>
        <time_frame>Baseline, 3 Months, 1 Year, and 5 Years post-implant</time_frame>
        <population>The outcome is reported for subjects who received the Edwards Intuity model 8300ACA or 8300ACB device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>INTUITY Aortic Valve and INTUITY Delivery System</title>
            <description>The EDWARDS INTUITY Aortic Valve models 8300ACA and 8300ACB, and the EDWARDS INTUITY Delivery System models 8300DCA and 8300DCB are intended for use in subjects with aortic stenosis or stenosis-insufficiency requiring primary replacement of the native aortic valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Red Blood Cells Count Over Time.</title>
          <description>Laboratory Analysis of Red Blood Cell Count on blood drawn from subjects; RBC carry oxygen.</description>
          <population>The outcome is reported for subjects who received the Edwards Intuity model 8300ACA or 8300ACB device where data is available.</population>
          <units>10^6 cells/microliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.30" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="257"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.40" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.36" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.35" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average Hemoglobin Count Over Time.</title>
        <description>Laboratory Analysis of Hemoglobin Count on blood drawn from subjects. Hemoglobin is an oxygen-carrying protein in red blood cells.</description>
        <time_frame>Baseline, 3 Months, 1 Year, and 5 Years post-implant</time_frame>
        <population>The outcome is reported for subjects who received the Edwards Intuity model 8300ACA or 8300ACB device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>INTUITY Aortic Valve and INTUITY Delivery System</title>
            <description>The EDWARDS INTUITY Aortic Valve models 8300ACA and 8300ACB, and the EDWARDS INTUITY Delivery System models 8300DCA and 8300DCB are intended for use in subjects with aortic stenosis or stenosis-insufficiency requiring primary replacement of the native aortic valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Hemoglobin Count Over Time.</title>
          <description>Laboratory Analysis of Hemoglobin Count on blood drawn from subjects. Hemoglobin is an oxygen-carrying protein in red blood cells.</description>
          <population>The outcome is reported for subjects who received the Edwards Intuity model 8300ACA or 8300ACB device where data is available.</population>
          <units>g/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="286"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.87" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="257"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.49" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.00" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.16" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average Hematocrit Percentage Over Time.</title>
        <description>Laboratory Analysis of Hematocrit Percentage on blood drawn from subjects. Hematocrit is the proportion of red blood cells to the fluid component (plasma) in the blood.</description>
        <time_frame>Baseline, 3 Months, 1 Year, and 5 Years post-implant</time_frame>
        <population>The outcome is reported for subjects who received the Edwards Intuity model 8300ACA or 8300ACB device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>INTUITY Aortic Valve and INTUITY Delivery System</title>
            <description>The EDWARDS INTUITY Aortic Valve models 8300ACA and 8300ACB, and the EDWARDS INTUITY Delivery System models 8300DCA and 8300DCB are intended for use in subjects with aortic stenosis or stenosis-insufficiency requiring primary replacement of the native aortic valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Hematocrit Percentage Over Time.</title>
          <description>Laboratory Analysis of Hematocrit Percentage on blood drawn from subjects. Hematocrit is the proportion of red blood cells to the fluid component (plasma) in the blood.</description>
          <population>The outcome is reported for subjects who received the Edwards Intuity model 8300ACA or 8300ACB device where data is available.</population>
          <units>percentage of red blood cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.29" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="257"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.07" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.93" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.58" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average Platelet Count Over Time.</title>
        <description>Laboratory Analysis of Platelet Count on blood drawn from subjects; platelets help with blood clotting.</description>
        <time_frame>Baseline, 3 Months, 1 Year, and 5 Years post-implant</time_frame>
        <population>The outcome is reported for subjects who received the Edwards Intuity model 8300ACA or 8300ACB device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>INTUITY Aortic Valve and INTUITY Delivery System</title>
            <description>The EDWARDS INTUITY Aortic Valve models 8300ACA and 8300ACB, and the EDWARDS INTUITY Delivery System models 8300DCA and 8300DCB are intended for use in subjects with aortic stenosis or stenosis-insufficiency requiring primary replacement of the native aortic valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Platelet Count Over Time.</title>
          <description>Laboratory Analysis of Platelet Count on blood drawn from subjects; platelets help with blood clotting.</description>
          <population>The outcome is reported for subjects who received the Edwards Intuity model 8300ACA or 8300ACB device where data is available.</population>
          <units>10^3 platelets per microliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="286"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220.33" spread="66.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223.07" spread="59.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="251"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213.22" spread="60.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.85" spread="63.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average Reticulocytes Percentage Over Time.</title>
        <description>Reticulocytes are immature red blood cells; a reticulocyte blood test measures the amount of these cells in the blood.</description>
        <time_frame>Baseline, 3 Months, 1 Year, and 5 Years post-implant</time_frame>
        <population>The outcome is reported for subjects who received the Edwards Intuity model 8300ACA or 8300ACB device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>INTUITY Aortic Valve and INTUITY Delivery System</title>
            <description>The EDWARDS INTUITY Aortic Valve models 8300ACA and 8300ACB, and the EDWARDS INTUITY Delivery System models 8300DCA and 8300DCB are intended for use in subjects with aortic stenosis or stenosis-insufficiency requiring primary replacement of the native aortic valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Reticulocytes Percentage Over Time.</title>
          <description>Reticulocytes are immature red blood cells; a reticulocyte blood test measures the amount of these cells in the blood.</description>
          <population>The outcome is reported for subjects who received the Edwards Intuity model 8300ACA or 8300ACB device where data is available.</population>
          <units>percentage of reticulocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="194"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.13" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.59" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.07" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average Haptoglobin Measurement Over Time.</title>
        <description>Laboratory Analysis of Haptoglobin on blood drawn from subjects; Haptoglobin is a protein produced by the liver.</description>
        <time_frame>Baseline, 3 Months, 1 Year, and 5 Years post-implant</time_frame>
        <population>The outcome is reported for subjects who received the Edwards Intuity model 8300ACA or 8300ACB device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>INTUITY Aortic Valve and INTUITY Delivery System</title>
            <description>The EDWARDS INTUITY Aortic Valve models 8300ACA and 8300ACB, and the EDWARDS INTUITY Delivery System models 8300DCA and 8300DCB are intended for use in subjects with aortic stenosis or stenosis-insufficiency requiring primary replacement of the native aortic valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Haptoglobin Measurement Over Time.</title>
          <description>Laboratory Analysis of Haptoglobin on blood drawn from subjects; Haptoglobin is a protein produced by the liver.</description>
          <population>The outcome is reported for subjects who received the Edwards Intuity model 8300ACA or 8300ACB device where data is available.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="202"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.08" spread="69.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.15" spread="81.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.65" spread="80.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.36" spread="81.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subject's Average Serum LDH Measurement Over Time.</title>
        <description>The lactate dehydrogenase (LDH) test looks for signs of damage to the body's tissues.</description>
        <time_frame>Baseline, 3 Months, 1 Year, and 5 Years post-implant</time_frame>
        <population>The outcome is reported for subjects who received the Edwards Intuity model 8300ACA or 8300ACB device where data is available.</population>
        <group_list>
          <group group_id="O1">
            <title>INTUITY Aortic Valve and INTUITY Delivery System</title>
            <description>The EDWARDS INTUITY Aortic Valve models 8300ACA and 8300ACB, and the EDWARDS INTUITY Delivery System models 8300DCA and 8300DCB are intended for use in subjects with aortic stenosis or stenosis-insufficiency requiring primary replacement of the native aortic valve.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Average Serum LDH Measurement Over Time.</title>
          <description>The lactate dehydrogenase (LDH) test looks for signs of damage to the body's tissues.</description>
          <population>The outcome is reported for subjects who received the Edwards Intuity model 8300ACA or 8300ACB device where data is available.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223.91" spread="53.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="242"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="271.37" spread="87.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250.56" spread="76.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="254.46" spread="76.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Events occurring from baseline through five years post-implant</time_frame>
      <desc>The outcome is reported for subjects who received the Edwards Intuity model 8300ACA or 8300ACB device where data is available.</desc>
      <group_list>
        <group group_id="E1">
          <title>INTUITY Aortic Valve and INTUITY Delivery System</title>
          <description>The EDWARDS INTUITY Aortic Valve models 8300ACA and 8300ACB, and the EDWARDS INTUITY Delivery System models 8300DCA and 8300DCB are intended for use in subjects with aortic stenosis or stenosis-insufficiency requiring primary replacement of the native aortic valve.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="233" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding - Gastrointestinal</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Bleeding - Post-Procedural</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Bleeding - Other</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Bleeding - Anticoagulant Related</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Bleeding - Hematoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Bleeding - Pericardial Tamponade</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Bleeding - Hemolysis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Bleeding - Procedural</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Embolic Event - Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Bleeding - Intracranial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac - Other</sub_title>
                <counts group_id="E1" events="35" subjects_affected="32" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - Heart Failure</sub_title>
                <counts group_id="E1" events="26" subjects_affected="20" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - Other Arrhythmia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - AV Block III</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Embolic Event - Stroke</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - Hypertension</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - Atrial Flutter</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - Pericardial Effusion</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Embolic Event - TIA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - Cardiac Arrest</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - Myocardial Infarction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - Angina, Stable</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - Angina, Unstable</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - Bradycardia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Vascular - Deep Vein Thrombosis (DVT)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - Supraventricular Tachycardia (SVT)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Valvular - Paravalvular Leak - Moderate</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - Aortic Dissection - Type A</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - Aortic Dissection - Type B</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - AV Block II</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - Cardiogenic Shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - Pericardial Tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - Ventricular Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Embolic Event - Peripheral Embolic Event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Valvular - Aortic Regurgitation - Moderate-Severe</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Valvular - Mitral Regurgitation - Mild-Moderate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Valvular - Mitral Regurgitation - Moderate-Severe</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Valvular - Other Mitral Valve</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Valvular - Paravalvular Leak - Mild</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Vascular - Vascular Access Site Complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal - Other</sub_title>
                <counts group_id="E1" events="34" subjects_affected="26" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="206" subjects_affected="137" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Other - Anemia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="25" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Other - Allergic Reaction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Multisystem Organ Failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic - Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hepatic - Liver Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" events="45" subjects_affected="37" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Infection - Local</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Infection - Pneumonia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Infection - Sternal Wound Infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Infection - Sepsis/Septicemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Infection - Bacteremia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Infection - Endocarditis (Aortic Valve)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Infection - Endocarditis (Mitral Valve)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Infection - Systemic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal - Renal Failure</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Renal - Renal Dysfunction</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Renal - Other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary - Pleural Effusion</sub_title>
                <counts group_id="E1" events="60" subjects_affected="57" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pulmonary - Other</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pulmonary - Respiratory Dysfunction/Insufficiency</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pulmonary - Respiratory Failure</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pulmonary - Pneumothorax</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Embolic Event - Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pulmonary - Atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pulmonary - Pulmonary Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pulmonary - Pulmonary Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular - Other</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="189" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding - Hematoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Bleeding - Other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Bleeding - Anticoagulant Related</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Bleeding - Gastrointestinal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Embolic Event - Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Embolic Event - Stroke</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Embolic Event - TIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Bleeding - Hemolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Bleeding - Heparin Induced Thrombocytopenia (HITS)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Embolic Event - Peripheral Embolic Event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac - Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="43" subjects_affected="43" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - BBB - Left Complete</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Valvular - Mitral Regurgitation - Mild</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - Other</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - BBB - Left Partial</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - Other Arrhythmia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - Atrial Flutter</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Valvular - Aortic Regurgitation - Mild</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - BBB - Right Complete</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Vascular - Deep Vein Thrombosis (DVT)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - AV Block I</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - Bradycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - Ventricular Tachycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Valvular - Aortic Stenosis - Moderate</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - AV Block III</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - Pericardial Effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - Angina, Stable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - Heart Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac - Supraventricular Tachycardia (SVT)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Valvular - Aortic Regurgitation - Mild-Moderate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Valvular - Aortic Stenosis - Mild</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Valvular - Aortic Stenosis - Severe</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Valvular - Mitral Regurgitation - Moderate-Severe</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Valvular - Other Mitral Valve</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Valvular - Other Tricuspid Valve</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Valvular - Paravalvular Leak - Mild/Moderate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Valvular - Paravalvular Leak - Moderate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Valvular - Paravalvular Leak - Trace/Trivial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Valvular - Structural Deterioration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Valvular - Tricuspid Regurgitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Vascular - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal - Other</sub_title>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hepatic - Other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="128" subjects_affected="85" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Other - Anemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Other - Allergic Reaction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Other</sub_title>
                <counts group_id="E1" events="50" subjects_affected="45" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Infection - Local</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Infection - Pneumonia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Infection - Sternal Wound Infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Infection - Bacteremia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Infection - Systemic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal - Renal Dysfunction</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Renal - Other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary - Pleural Effusion</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pulmonary - Other</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pulmonary - Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pulmonary - Pulmonary Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pulmonary - Respiratory Dysfunction/Insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pulmonary - Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication of overall study results which have not been released requires written approval of Sponsor, but presentation of site-specific results can occur subject to review by Sponsor. Manuscripts will be submitted to Sponsor for review 60 days prior to submission of manuscript for publication/presentation. Sponsor may ask for a 90 day delay of submission of manuscripts for publication to protect proprietary information and filing of related patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrey Nersesov, Sr. Director of Clinical Affairs, Surgical Structural Heart</name_or_title>
      <organization>Edwards Lifesciences, LLC</organization>
      <phone>949-250-2500 ext 0225</phone>
      <email>Andrey_Nersesov@edwards.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

